Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This decision was based on business considerations and not due to specific safety reasons or a request from a regulatory authority.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-15 | estimated | When the study began enrolling |
| Primary completion | 2026-04-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-13 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-11-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Ovarian Cancer
- Liposarcoma
- Non-small Cell Lung Cancer (NSCLC)
- Endometrial
- Solid Tumors
Interventions
- Drug: PF-07224826
- Combination product: Fulvestrant
- Drug: PF-07224826
- Combination product: Fulvestrant
- Drug: PF-07224826
- Combination product: Fulvestrant
- Drug: PF-07224826
- Combination product: Fulvestrant
- Drug: PF-07224826
- Combination product: Fulvestrant
- Drug: PF-07224826
- Combination product: Fulvestrant
- Drug: PF-07224826
- Combination product: Fulvestrant
Primary outcomes
what the primary-completion date above is the date OFPart 1: First cycle dose limiting toxicities (DLTs)
measured Cycle 1 (28 days)
Part 1 and Part 2: Adverse events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0), timing, seriousness and relationship to study therapy.
measured From the first dose to earliest of 28 days post last dosing date or day of new anticancer therapy -1 day.
Part 1 and Part 2: Number of participants with Clinical Laboratory abnormalities
measured From the first dose to earliest of 28 days post last dosing date or day of new anticancer therapy -1 day.
Part 1 and Part 2: Incidence of clinically significant abnormal vital signs.
measured From the first dose to earliest of 28 days post last dosing date or day of new anticancer therapy -1 day.
Part 2: Preliminary antitumor activity measure for efficacy includes ORR, as assessed using RECIST version 1.1.
measured From baseline until the date of first documented progression, or date of death of any cause, or date of withdrawal of consent, or date of lost to follow-up, whichever came first.
Part 1 and Part 2: Incidence of clinically significant abnormal ECGs.
measured From the first dose to earliest of 28 days post last dosing date or day of new anticancer therapy -1 day.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed